Short-term light sedation with remimazolam besylate versus propofol in the ICU (SHOSREB): a multicentre, randomized, single-blind, controlled trial - PubMed
4 hours ago
- #ICU Sedation
- #Remimazolam
- #Propofol
- The SHOSREB trial compared short-term light sedation using remimazolam besylate versus propofol in mechanically ventilated ICU patients.
- The primary outcome was successful sedation, defined as maintaining RASS scores between -2 and +1 for at least 70% of infusion time without rescue sedatives.
- Results showed that 97.5% of participants in both groups achieved successful sedation, with remimazolam being non-inferior to propofol (difference of 0%, 95% CI -6.5% to 6.4%).
- There were no significant differences in the median infusion duration or the percentage of time within target RASS scores between the two groups.
- The study concluded that remimazolam besylate is non-inferior to propofol for short-term light sedation in the ICU.
- Conflict of interest disclosures note funding and drug support from Yichang Humanwell Pharmaceutical Co. Ltd., the manufacturer of remimazolam.